Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Litigation In Brief

This article was originally published in The Gray Sheet

Executive Summary

St. Jude angers investors: Multiple class action suits filed against the firm charge that it misled investors about its implantable cardioverter defibrillator sales in the fourth quarter of 2005 to inflate its stock price. Law firm Roy Jacobs & Associates, for one, charges that St. Jude reported false information to "achieve extraordinary personal benefits for top insiders, such as CEO Daniel J. Starks, who sold an unusual number of shares in the open market in the early months of 2006." The lawsuits come after St. Jude reported first quarter earnings April 4 of $784 mil., far below its previously projected sales of $799 mil.-$839 mil. (1"The Gray Sheet" April 10, 2006, p. 7)...

You may also be interested in...



Medtronic Launches First Products In Interventional Spine Unit

Medtronic's roll-out of its Arcuate minimally invasive cement delivery systems for vertebral compression fractures marks the commercial debut of its fledgling Interventional Spine unit, formed last spring

Medtronic Launches First Products In Interventional Spine Unit

Medtronic's roll-out of its Arcuate minimally invasive cement delivery systems for vertebral compression fractures marks the commercial debut of its fledgling Interventional Spine unit, formed last spring

Personalized Medicine To Be HHS Focus In Administration’s Final Years

Facilitating the development of personalized medicine will be a priority for HHS during the remainder of the Bush Administration, according to HHS Secretary Michael Leavitt

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel